In patients with head and neck cancer, a strategy to reduce the radiation dose to dysphagia-and aspiration-related structures improved swallowing and other functional outcomes compared with standard ...

Intensity-modulated radiation therapy (IMRT) should be the preferred choice when treating patients with locally advanced non-small cell lung cancer (NSCLC), as it reduces radiation exposure to the ...

Please provide your email address to receive an email when new articles are posted on . Men with low- or intermediate-risk prostate cancer achieved similar quality-of-life outcomes whether they ...

The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...

A new phase III clinical trial finds that intensity-modulated radiation therapy (IMRT) and proton beam therapy resulted in similar quality-of-life outcomes and low rates of side effects for people ...

According to preliminary data from a multi-institution Phase III trial intensity modulated proton therapy (IMPT) achieved similar clinical outcomes and offered significant patient benefits when ...

Of the 300 patients in the PARCER trial, 93 faced grades ≥2 adverse events (3D-CRT = 59, IG-IMRT = 34). Patients in the 3D-CRT and IG-IMRT arms spent an average of 2.39 years and 1.96 years in ...

The visual nature of head and neck cancer calls for treatment strategies that will minimize toxicities related to radiation therapy. Advances in precision radiation techniques, supportive care, and ...

Intensity-modulated radiotherapy is as good as proton beam therapy for treating people with head and neck cancer, according to the results of a Cancer Research UK-funded clinical trial. The TORPEdO ...

Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children’s Oncology Group AREN0321 Study This phase IIB trial ...

Proton beam therapy does not improve the patient-reported outcome of bowel function compared with IMRT. Bowel side effects do not differ between patients with localized prostate cancer who receive ...